Figure 1From: Safety and feasibility of adjuvant chemotherapy with S-1 in Japanese breast cancer patients after primary systemic chemotherapy: a feasibility studyCumulative percentage of S-1 administration for 365 days. Censoring ticks show the patients who discontinued S-1 because of adverse event, patient refusal, or recurrence.Back to article page